Therefore, we measured serum levels of the key biomarkers, IgA, Gd-IgA1, Gd-IgA1-specific IgG and Gd-IgA1-specific IgA to assess their utility in distinguishing patients with IgAN from patients with other forms of kidney disease and healthy controls. This evidence concerns the gene CD79A and kidney disorder.